We view today's CE approval for XVIVO's heart technology very positively, removing one of the key regulatory overhangs in the case and pavin...
The report reinforced our positive view on Xvivo's underlying sales development, with heart sales clearly exceeding our expectations.
Redeye shares its preview of Xvivo’s Q2 2026 results, due on July 14.
The report supported our take on increasing thoracic sales and showed continued FCF improvements (Q4 was the first quarter of positive cash ...
Xvivo demonstrated once again that it is back on track and generating positive free cash flow.
Redeye shares its preview of Xvivo’s Q1 2026 results, due on April 24.
Redeye returns with a more in-depth take on Xvivo’s Q4 report.
We expect a strong positive share price reaction today of c15%, given the beat on sales, profitability and a positive free cash flow.
Redeyes shares its preview of Xvivo’s Q4 2025 results, due on January 27.
Redeye argues that the negative YTD share price performance does not reflect Xvivo’s underlying fundamental developments.
Redeye gives its initial take on Xvivo’s Q3 report.
Redeye shares its preview of Xvivo’s Q3 2025 results, due October 23.
The delayed launch is a setback for both XVIVO, patients and specialist centers waiting to use the solution.
The organic CER growth at -11% is a major negative surprise, and the H1 organic CER growth is 1%.
The 12-month safety results confirm and extend the earlier results after 3 months, adding support both ahead of the European, Canadian and U...
Q1 is spot on expectations in most aspects. The organic CER growth of 14% is expected to improve with higher delivery capacity and solid dem...
As expected, Q1 is a modest quarter after an extended period of high organic growth.
XVIVO is likely to enter 2025 with a modest quarter during a period of macro-economic worries.
Medtech is not exempt from US reciprocal tariffs, unlike Pharma.
A demanding comparable quarter, temporary negative quarterly deviations, and weekly phasing are transient, especially when the structural gr...
XVIVO Q4 is another solid quarter with 44% organic growth (CER), 6-7% above expectations.
Q4 is another solid quarter with 44% organic growth (CER), 6-7% above expectations.
XVIVO delivers impressive organic growth with reported sales below market expectations due to FX (currency) headwind.
XVIVO delivers a Q3 that aligns with our expectations but is below market expectations due to FX headwind.
XVIVO delivered an organic growth surprise at 32% (CER, 32% in Q1) during Q2 a quarter, with a substantial contribution from both the thorac...
XVIVO delivered a positive surprise in Q2 with organic growth of 35% which was well ahead of the already improved earlier quarter, Redeye’s ...
See what other investors are asking and the answers from Redeye's dedicated analyst in the latest Analyst Q&A.
XVIVO delivered an organic growth surprise at 32% (CER) during Q1 a quarter, with a substantial contribution from both the thoracic and abdo...
XVIVO improved its organic growth to 32% compared with the unusually modest 12% level in Q4 2023.
XVIVO presented the overall results from the European Heart study, based on 203 patients across 15 centers in 8 countries.
Redeye updates our outlook after Q4 2023. XVIVO delivers improved gross margins with a softer organic growth of 12% (CER) and a quarter with...
XVIVO delivers a soft 12% organic growth in the last quarter of 2023 (based on CER excluding acquisition support).
XVIVO’s future competitor in both the US Heart, Lung and Liver segment reported strong growth late yesterday.
Redeye updates our outlook after Q3. XVIVO delivers a improved gross and EBITDA margins and an overall organic growth of 42% (CER) which is ...
XVIVO delivers both improved Gross- and EBITDA margins and an overall organic growth of 42% (CER) which is very good by most comparisons.
XVIVO’s Q3 comes after the SEK 440m directed share issue and before launching the US Heart study.
Redeye updates our outlook after the SEK 440m (gross) directed rights issue priced at SEK 275, will allow XVIVO to push the Liver Assist and...
The SEK 440m (gross) directed rights issue priced at SEK 275, will allow XVIVO to push the Liver Assist and the Heart solution onto the US m...
Redeye updates our outlook ahead of the European and the US launch of XVIVO’s Heart cold continuous oxygenated perfusion solution.
XVIVO’s peer and future competitor TransMedics continues to open up the US Heart transplant market with its OCS Heart Perfusion System.
We expect XVIVO to initiate the US study during early Q4 2023 and the inclusion of donation after circulatory death (DCD) hearts is very pos...
Redeye updates our outlook after Q2. XVIVO’s result indicated a mix of organisational improvements and strong demand.
The organic (CER) growth was 46% which is a step up versus Q1 and the gross margins improves to 74.
Redeye updates our outlook after Q1. XVIVO’s result indicated a mix of organisational improvements and strong demand.
XVIVO has performed well in 2023. Both the organic growth (35%) and the improved gross margins (74.
Redeye updates our outlook after Q4 2022 XVIVO. The result confirms that the key value drivers are on fire and the outlook is positive.
The most important aspects are organic growth and gross margins in our view.
The initial topp-line result is positive and we look forward to the full results during Q2 2023.
XVIVO delivers a Q3 with 35% organic (CER) growth which is booth solid and ahead of our expectations.
XVIVO: A very sad day
XVIVO’s financial target is to reach above an EBIT margin of 20% and above EBITDA margins of 30% supported by among other value drivers, the...
The Breakthrough Device Designation (BDD) is a timely stepping stone for XVIVO and the Liver Assist solution.
Redeye updates our outlook on XVIVO. The company had underperformed the local equity market despite validating its growth capacity and abili...
The Thoracic recovery continues, and the organic growth in constant currencies is a robust 24% compared with 32% in the earlier Q1.
The Thoracic recovery continues, and together with well-balanced and high organic growth, we expect the initial soft reaction evolves into v...
The Thoracic business delivers CER organic growth of 82% with improved gross margins with significant US support.
